Javascript must be enabled to continue!
Oxycodone-related side effects: Impact on degree of bother, adherence, pain relief, satisfaction, and quality of life
View through CrossRef
Objectives: Oxycodone immediate-release, alone or in combination (hereafter, oxycodone), is widely used to treat pain and is often associated with bothersome side effects. The objective was to assess side effect frequency, degree of bother, and impact on health-related quality of life (HRQoL).Methods: An online survey was completed by a nationwide convenience sample of patients currently taking oxycodone for nonmalignant pain. Detailed data on any oxycodone-related side effects were collected. Relationships between side effects, pain relief, and HRQoL (Physical Component Summary [PCS] and Mental Component Summary [MCS] of the Short Form 12-Item Health Survey) were explored.Results: Among 601 respondents (average 45 years, 85.0 percent Caucasian, 69.1 percent female, 61.1 percent on oxycodone > 30 days), 84.0 percent were bothered by side effects with 30.8 percent quite a bit or extremely bothered. Over half were bothered by drowsiness (56.2 percent) and constipation (53.1 percent), over two-fifths by lightheadedness (43.6 percent) and dizziness (42.1 percent), approximately one-third by headache (33.1 percent) and nausea (31.3 percent), 27.6 percent itching, and 14.8 percent vomiting, which affected adherence to prescribed dosing regimens and, thus, is inversely associated with the level of pain relief. Patients who experienced less than 50 percent pain relief from oxycodone had worse PCS (33.9 vs 35.7; p = 0.038) and MCS (38.5 vs 42.4; p < 0.001) scores when compared with those who experienced 50 percent or more pain relief.Conclusions: The majority of survey respondents experienced side effects of oxycodone, with a majority being bothered by side effects and impacting their QoL. This raises a question about the unmet need for pain medications with improved side effect profiles.
Title: Oxycodone-related side effects: Impact on degree of bother, adherence, pain relief, satisfaction, and quality of life
Description:
Objectives: Oxycodone immediate-release, alone or in combination (hereafter, oxycodone), is widely used to treat pain and is often associated with bothersome side effects.
The objective was to assess side effect frequency, degree of bother, and impact on health-related quality of life (HRQoL).
Methods: An online survey was completed by a nationwide convenience sample of patients currently taking oxycodone for nonmalignant pain.
Detailed data on any oxycodone-related side effects were collected.
Relationships between side effects, pain relief, and HRQoL (Physical Component Summary [PCS] and Mental Component Summary [MCS] of the Short Form 12-Item Health Survey) were explored.
Results: Among 601 respondents (average 45 years, 85.
0 percent Caucasian, 69.
1 percent female, 61.
1 percent on oxycodone > 30 days), 84.
0 percent were bothered by side effects with 30.
8 percent quite a bit or extremely bothered.
Over half were bothered by drowsiness (56.
2 percent) and constipation (53.
1 percent), over two-fifths by lightheadedness (43.
6 percent) and dizziness (42.
1 percent), approximately one-third by headache (33.
1 percent) and nausea (31.
3 percent), 27.
6 percent itching, and 14.
8 percent vomiting, which affected adherence to prescribed dosing regimens and, thus, is inversely associated with the level of pain relief.
Patients who experienced less than 50 percent pain relief from oxycodone had worse PCS (33.
9 vs 35.
7; p = 0.
038) and MCS (38.
5 vs 42.
4; p < 0.
001) scores when compared with those who experienced 50 percent or more pain relief.
Conclusions: The majority of survey respondents experienced side effects of oxycodone, with a majority being bothered by side effects and impacting their QoL.
This raises a question about the unmet need for pain medications with improved side effect profiles.
Related Results
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Abstract
Thoracic outlet syndrome (TOS) is a complex and often overlooked condition caused by the compression of neurovascular structures as they pass through the thoracic outlet. ...
Double‐Blind, Randomized Comparison of the Analgesic and Pharmacokinetic Profiles of Controlled‐ and Immediate‐Release Oral Oxycodone in Cancer Pain Patients
Double‐Blind, Randomized Comparison of the Analgesic and Pharmacokinetic Profiles of Controlled‐ and Immediate‐Release Oral Oxycodone in Cancer Pain Patients
Thirty patients with cancer pain completed a double‐blind crossover study comparing controlled‐release (CR) and immediate‐release (IR) oxycodone. In open‐label titration (2 to 21 d...
[RETRACTED] Keanu Reeves CBD Gummies v1
[RETRACTED] Keanu Reeves CBD Gummies v1
[RETRACTED]Keanu Reeves CBD Gummies ==❱❱ Huge Discounts:[HURRY UP ] Absolute Keanu Reeves CBD Gummies (Available)Order Online Only!! ❰❰= https://www.facebook.com/Keanu-Reeves-CBD-G...
Monitoring oxycodone use in patients with chronic pain: Analysis of oxycodone and metabolite excretion in saliva and urine
Monitoring oxycodone use in patients with chronic pain: Analysis of oxycodone and metabolite excretion in saliva and urine
Objective: Saliva is purported to have a close correspondence to plasma concentrations due to a passive diffusion process from plasma to saliva. However, limited data are available...
Efficacy and tolerability of oral morphine versus oxycodone/acetaminophen for analgesia in the emergency department
Efficacy and tolerability of oral morphine versus oxycodone/acetaminophen for analgesia in the emergency department
Objective: Oxycodone/acetaminophen is one of the most commonly prescribed medications for pain management in the emergency department (ED) despite its high abuse liability. Our obj...
Oxycodone hydrochloride controlled‐release tablets (OxyContin®): post‐marketing surveillance (PMS) study for relieving moderate to severe non‐cancer pain
Oxycodone hydrochloride controlled‐release tablets (OxyContin®): post‐marketing surveillance (PMS) study for relieving moderate to severe non‐cancer pain
Objective: To evaluate the efficacy and safety of oxycodone hydrochloride controlled‐release (CR) tablets (Oxycontin®, Mundipharma International Limited, Cambridge, UK), 5 mg, 10 m...
Oxycodone 5 Miligram is More Effective Than Ketorolac 30 Miligram in Suppressing Cortisol Levels During General Anesthesia
Oxycodone 5 Miligram is More Effective Than Ketorolac 30 Miligram in Suppressing Cortisol Levels During General Anesthesia
Background: Preemptive analgesia is a developing clinical concept, which involves administering analgesics before pain stimulation occurs, to prevent the sensitization of the nervo...
Decreased responsiveness to oxycodone: A case of a pharmacokinetic drug interaction?
Decreased responsiveness to oxycodone: A case of a pharmacokinetic drug interaction?
Concurrent administration of oxycodone and phenytoin may cause, through induction of CYP3A4 enzymes, decreased analgesic effects of oxycodone. However, no descriptions of this inte...

